August 2013 in “Fertility and Sterility” PCOS may be influenced by factors in the blood, not just the ovaries.
January 2012 in “Durham e-Theses (Durham University)” Keratin 15 affects cell behavior and characteristics in skin cells.
April 2010 in “The Journal of Urology” Human prostate cells produce more WISP1/CCN4 when there's not enough oxygen.
April 2010 in “The Journal of Urology” The research found that androgens help control blood flow in the rat prostate through a specific binding site.
November 2009 in “Regenerative Medicine” The regenerative medicine industry saw business growth with new partnerships, clinical trials, and financial investments.
August 2007 in “Journal of Investigative Dermatology” The meeting discussed vitamin D3's role in fighting tuberculosis, potential treatments for skin conditions like psoriasis, and hair follicle regeneration as a possible solution for hair loss.
March 2010 in “The Journal of Urology” Hair loss, prostate size, and urinary issues are related due to androgen effects.
23 citations
,
March 2019 in “AIDS Care” Remembering to take PrEP is the main challenge, and urine monitoring is a preferred adherence method.
16 citations
,
October 2013 in “Irish Veterinary Journal” Oral feline interferon-omega improved symptoms in diabetic cats with gingivostomatitis.
6 citations
,
May 2013 in “Journal of Clinical Oncology” Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
20 citations
,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
47 citations
,
June 2011 in “Movement Disorders” The LRRK2-G2019S mutation in Parkinson's disease has a lifetime penetrance of 25-35%, and finasteride may help reduce symptoms in adult male Tourette syndrome patients.
October 2021 in “International journal of basic and clinical pharmacology” Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
1 citations
,
August 2018 in “bioRxiv (Cold Spring Harbor Laboratory)” A new mutation in the TMEM173 gene and a risk allele in IFIH1 cause a unique set of immune-related symptoms.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
December 2023 in “Journal of Multiple Sclerosis and Neuroimmunology” Teriflunomide can cause hair thinning.
3 citations
,
January 2019 in “Bulgarian Journal of Veterinary Medicine” The cat was put to sleep due to recurring infections.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
1 citations
,
April 2020 in “medRxiv (Cold Spring Harbor Laboratory)” The study found that Tourette Syndrome may be linked to certain immune system processes and synaptic signaling.
COVID-19 vaccines had more side effects and worse perception than flu vaccines in Korean lupus patients.
February 2025 in “Infectious Diseases & Immunity” HHV-6 reactivation may be linked to psychiatric disorders and can improve with antiviral treatment.
8 citations
,
January 2022 in “Infectious diseases News Opinions Training” Genetic differences affect COVID-19 severity and treatment effectiveness.
36 citations
,
March 2014 in “Annals of the Rheumatic Diseases” Activating liver X receptors can reduce fibrosis by stopping certain immune cells from releasing harmful proteins.
15 citations
,
January 2014 in “Dermatology” Some patients treated with peginterferon and ribavirin for chronic hepatitis C had mild to moderate skin reactions, but treatment did not need to be stopped.
4 citations
,
August 2023 in “Biomedicine & Pharmacotherapy” Ivacaftor can protect against noise-induced hearing loss by reducing oxidative stress.
38 citations
,
January 2020 in “Cell Transplantation” Targeting ACE2 and TMPRSS2 may help prevent or treat COVID-19 in cancer patients.
January 2013 in “Biology of blood and marrow transplantation” Rapamycin increased survival in mice with severe chronic graft-versus-host disease by expanding regulatory T cells.
January 2024 in “Wiadomości Lekarskie” Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.
71 citations
,
May 2024 in “New England Journal of Medicine” Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.
CRISPR gene editing reduces harmful molecules in cells from Emery–Dreifuss Muscular Dystrophy patients.